Bank of New York Mellon’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-128,347
| Closed | -$630K | – | 4700 |
|
|
2021
Q3 | $630K | Buy |
128,347
+46,220
| +56% | +$224K | ﹤0.01% | 3667 |
|
|
2021
Q2 | $433K | Sell |
82,127
-3,128
| -4% | -$16.2K | ﹤0.01% | 3838 |
|
|
2021
Q1 | $409K | Sell |
85,255
-2,796
| -3% | -$14.6K | ﹤0.01% | 3796 |
|
|
2020
Q4 | $381K | Buy |
88,051
+32,737
| +59% | +$140K | ﹤0.01% | 3741 |
|
|
2020
Q3 | $227K | Buy |
55,314
+41,308
| +295% | +$160K | ﹤0.01% | 3808 |
|
|
2020
Q2 | $36K | Sell |
14,006
-65,907
| -82% | -$194K | ﹤0.01% | 4018 |
|
|
2020
Q1 | $231K | Sell |
79,913
-536
| -0.7% | -$2.4K | ﹤0.01% | 3694 |
|
|
2019
Q4 | $305K | Sell |
80,449
-2,093
| -3% | -$10K | ﹤0.01% | 3796 |
|
|
2019
Q3 | $422K | Sell |
82,542
-2,006
| -2% | -$12.4K | ﹤0.01% | 3636 |
|
|
2019
Q2 | $524K | Sell |
84,548
-4,824
| -5% | -$27.8K | ﹤0.01% | 3575 |
|
|
2019
Q1 | $635K | Buy |
89,372
+1,966
| +2% | +$17.7K | ﹤0.01% | 3433 |
|
|
2018
Q4 | $746K | Sell |
87,406
-161,336
| -65% | -$2.1M | ﹤0.01% | 3268 |
|
|
2018
Q3 | $4.98M | Buy |
248,742
+2,390
| +1% | +$56.1K | ﹤0.01% | 2419 |
|
|
2018
Q2 | $6.36M | Buy |
246,352
+27,696
| +13% | +$767K | ﹤0.01% | 2263 |
|
|
2018
Q1 | $5.23M | Buy |
218,656
+107,835
| +97% | +$3.4M | ﹤0.01% | 2330 |
|
|
2017
Q4 | $3.75M | Buy |
110,821
+49,548
| +81% | +$1.38M | ﹤0.01% | 2486 |
|
|
2017
Q3 | $1.3M | Sell |
61,273
-2,064
| -3% | -$37.8K | ﹤0.01% | 3086 |
|
|
2017
Q2 | $1.11M | Sell |
63,337
-2,493
| -4% | -$41.2K | ﹤0.01% | 3193 |
|
|
2017
Q1 | $1.15M | Buy |
65,830
+1,563
| +2% | +$26.6K | ﹤0.01% | 3163 |
|
|
2016
Q4 | $1.09M | Buy |
64,267
+7,334
| +13% | +$113K | ﹤0.01% | 3217 |
|
|
2016
Q3 | $935K | Sell |
56,933
-3,349
| -6% | -$50.9K | ﹤0.01% | 3213 |
|
|
2016
Q2 | $912K | Buy |
60,282
+10,802
| +22% | +$178K | ﹤0.01% | 3202 |
|
|
2016
Q1 | $715K | Sell |
49,480
-11,719
| -19% | -$197K | ﹤0.01% | 3252 |
|
|
2015
Q4 | $1.73M | Buy |
61,199
+5,248
| +9% | +$88.3K | ﹤0.01% | 2806 |
|
|
2015
Q3 | $937K | Buy |
55,951
+1,071
| +2% | +$24.4K | ﹤0.01% | 3223 |
|
|
2015
Q2 | $1.44M | Buy |
54,880
+20,716
| +61% | +$403K | ﹤0.01% | 3131 |
|
|
2015
Q1 | $597K | Buy |
34,164
+2,069
| +6% | +$35.5K | ﹤0.01% | 3535 |
|
|
2014
Q4 | $557K | Buy |
+32,095
| New | +$487K | ﹤0.01% | 3576 |
|
Bank of New York Mellon's ADMS Position: Q4 2021 in Review
Bank of New York Mellon sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 128,347 shares — an estimated $630K sold.
Bank of New York Mellon first reported a position in ADMS in Q4 2014 and held it in 28 quarters. The position peaked at $6.36M in Q2 2018. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- Bank of New York Mellon reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Bank of New York Mellon sold 128,347 Adamas Pharmaceuticals shares in Q4 2021, an estimated $630K.
- Bank of New York Mellon first reported a position in Adamas Pharmaceuticals in Q4 2014 and held it in 28 quarters.
- Bank of New York Mellon's Adamas Pharmaceuticals position peaked at $6.36M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Bank of New York Mellon's 13F filing for Q4 2021, filed 11 Feb 2022.